关于对滥用药物的实验室检测的ADLM指导文件,以支持紧急情况部门
Christine L H Snozek1, Matthew D Krasowski2, Jennifer M Colby3
1Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ, United States.
The journal of applied laboratory medicine
|January 6, 2026
概括
本指南为医院实验室提供了针对急诊室的尿液药物检测 (UDT) 的建议. 它涵盖了儿童和成人患者滥用药物或物质的检测指示,方法和解释.
科学领域:
- 临床化学 临床化学
- 毒理学 毒理学 毒理学
- 实验室医学 实验室医学
背景情况:
- 紧急部门 (ED) 要求对特定患者群体进行毒理测试,包括儿科和创伤.
- 历史上被称为"滥用药物" (DOA),这些物质需要更新,更少的污名化术语.
- 目前的指导方针缺乏DOA的替代术语,需要转向"滥用药物或物质".
研究的目的:
- 为美国医院实验室提供共识指导,在急诊室进行尿液药物测试 (UDT).
- 总结UDT和儿童和成人群体相关测试的指示.
- 推可用的快速回收测试,方法和报告标准.
主要方法:
- 文献审查和基于共识的建议.
- 免疫试验和质谱技术的分析,包括优点,缺点和挑战.
- 包括用于高级测试的指示,如新型精神活性物质.
主要成果:
- 总结了在儿童和成人患者中订购UDT的指示.
- 概述了易于获得的,快速回收测试的建议.
- 审查不同测试方法的优缺点和共同的挑战.
结论:
- 医院实验室应与ED,医疗毒理学家和毒药控制中心合作.
- 测试菜单应优化,以反映当地药物使用模式和临床需求.
- 实验室工作人员需要对测定局限性和结果的准确解释进行教育.
相关概念视频
Therapeutic Drug Monitoring: Drug Analysis Methods
172
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
172
Drug Concentrations: Measurements
1.0K
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
1.0K
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
179
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
179
Therapeutic Drug Monitoring: Overview and Classification
304
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
304
Therapeutic Drug Monitoring: Affecting Factors
196
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
196


